Literature DB >> 15646033

Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats.

Masahiro Sugano1, Tomoji Hata, Keiko Tsuchida, Nobuhiro Suematsu, Jun-Ichi Oyama, Shinji Satoh, Naoki Makino.   

Abstract

Apoptosis in the myocardium is linked to ischemia/reperfusion injury, and TNF-alpha induces apoptosis in cardiomyocytes. A significant amount of TNF-alpha is detected after ischemia and reperfusion. Soluble TNF-alpha receptor 1 (sTNFR1) is an extracellular domain of TNF-alpha receptor 1 and is an antagonist to TNF-alpha. In the present study, we examined the effects of sTNFR1 on infarct size in acute myocardial infarction (AMI) following ischemia/reperfusion. Male Wistar rats were subjected to left coronary artery (LCA) ligation. After 30 min of LCA occlusion, the temporary ligature on the LCA was released and blood flow was restored. Immediately after reperfusion, a total of 200 microg of sTNFR1 or LacZ plasmid was injected into three different sites of the left ventricular wall. At 6 h, 1 and 2 days after reperfusion, the TNF-alpha bioactivity in the myocardium was significantly higher in rats receiving LacZ plasmid than in sham-operated rats, whereas sTNFR1 plasmid significantly suppressed the increase in the TNF-alpha bioactivity. The sTNFR1 plasmid significantly reduced DNA fragmentation and caspase activity compared to the LacZ plasmid. Finally, the sTNFR1 expression-plasmid treatment significantly reduced the area of myocardial infarction at 2 days after ischemia/reperfusion compared to LacZ plasmid. In conclusion, the TNF-alpha bioactivity in the heart increased from the early stage of ischemia/reperfusion, and this increase was thought to contribute in part to the increased area of myocardial infarction. Suppression of TNF-alpha bioactivity with the sTNFR1 plasmid reduced the infarct size in AMI following ischemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15646033     DOI: 10.1023/b:mcbi.0000049149.03964.c9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

1.  Primary angioplasty versus thrombolysis in the treatment of acute myocardial infarction. ALKK Study Group.

Authors:  R Zahn; A Koch; J Rustige; R Schiele; A Wirtzfeld; K L Neuhaus; H Kuhn; H Gülker; J Senges
Journal:  Am J Cardiol       Date:  1997-02-01       Impact factor: 2.778

Review 2.  Modulation of leukocyte-mediated myocardial reperfusion injury.

Authors:  B R Lucchesi
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

3.  Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats.

Authors:  N Makino; T Hata; M Sugano; I M Dixon; T Yanaga
Journal:  J Mol Cell Cardiol       Date:  1996-03       Impact factor: 5.000

4.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

Authors:  D Bryant; L Becker; J Richardson; J Shelton; F Franco; R Peshock; M Thompson; B Giroir
Journal:  Circulation       Date:  1998-04-14       Impact factor: 29.690

5.  Myocardial reperfusion: a double-edged sword?

Authors:  E Braunwald; R A Kloner
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

6.  TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion.

Authors:  Kirstan K Meldrum; Daniel R Meldrum; Xianzhong Meng; Lihua Ao; Alden H Harken
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

7.  Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction.

Authors:  D Li; L Zhao; M Liu; X Du; W Ding; J Zhang; J L Mehta
Journal:  Am Heart J       Date:  1999-06       Impact factor: 4.749

8.  Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats.

Authors:  S Takeshita; T Isshiki; T Sato
Journal:  Lab Invest       Date:  1996-06       Impact factor: 5.662

9.  Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators.

Authors:  G W Stone; B R Brodie; J J Griffin; M C Morice; C Costantini; F G St Goar; P A Overlie; J J Popma; J McDonnell; D Jones; W W O'Neill; C L Grines
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

10.  Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion.

Authors:  J Gurevitch; I Frolkis; Y Yuhas; B Lifschitz-Mercer; E Berger; Y Paz; M Matsa; A Kramer; R Mohr
Journal:  J Am Coll Cardiol       Date:  1997-11-15       Impact factor: 24.094

View more
  10 in total

1.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.

Authors:  Rei Shibata; Kaori Sato; David R Pimentel; Yukihiro Takemura; Shinji Kihara; Koji Ohashi; Tohru Funahashi; Noriyuki Ouchi; Kenneth Walsh
Journal:  Nat Med       Date:  2005-09-11       Impact factor: 53.440

2.  Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNF-α in the retina.

Authors:  Shahid Husain; Gregory I Liou; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

3.  AMPK and TNF-alpha at the crossroad of cell survival and death in ischaemic heart.

Authors:  Wei Peng; Yan Zhang; Weizhong Zhu; Chun-Mei Cao; Rui-Ping Xiao
Journal:  Cardiovasc Res       Date:  2009-08-11       Impact factor: 10.787

4.  Disruption of group IVA cytosolic phospholipase A(2) attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway.

Authors:  Yukio Saito; Kazuhiro Watanabe; Daisuke Fujioka; Takamitsu Nakamura; Jun-ei Obata; Kenichi Kawabata; Yosuke Watanabe; Hideto Mishina; Shun Tamaru; Yoshihiro Kita; Takao Shimizu; Kiyotaka Kugiyama
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

5.  The extracellular matrix protein CCN1 dictates TNFα and FasL cytotoxicity in vivo.

Authors:  Chih-Chiun Chen; Vladislava Juric; Lester F Lau
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  TNF-α, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention.

Authors:  Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf
Journal:  Clin Res Cardiol       Date:  2012-05-06       Impact factor: 5.460

7.  The use of moderate hypothermia during cardiac surgery is associated with repression of tumour necrosis factor-alpha via inhibition of activating protein-1: an experimental study.

Authors:  Ma Qing; Michael Wöltje; Kathrin Schumacher; Magdalena Sokalska; Jaime F Vazquez-Jimenez; Ralf Minkenberg; Marie-Christine Seghaye
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

8.  3,3'-Diindolylmethane protects cardiomyocytes from LPS-induced inflammatory response and apoptosis.

Authors:  Qiang Luo; Ankang Yang; Quan Cao; Hongjing Guan
Journal:  BMC Pharmacol Toxicol       Date:  2018-11-09       Impact factor: 2.483

9.  Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction.

Authors:  Lennart Nilsson; Aleksander Szymanowski; Eva Swahn; Lena Jonasson
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Protective Effects of Kaempferol against Myocardial Ischemia/Reperfusion Injury in Isolated Rat Heart via Antioxidant Activity and Inhibition of Glycogen Synthase Kinase-3β.

Authors:  Mingjie Zhou; Huanhuan Ren; Jichun Han; Wenjuan Wang; Qiusheng Zheng; Dong Wang
Journal:  Oxid Med Cell Longev       Date:  2015-07-22       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.